Navigation Links
XTL Receives Staff Letter From NASDAQ; XTL may Transfer its ADR Listing to the NASDAQ Capital Market
Date:8/28/2007

t must meet certain financial requirements and adhere to NASDAQ's corporate governance standards.

About XTL Biopharmaceuticals Ltd.

XTL Biopharmaceuticals Ltd. ("XTL") is engaged in the acquisition, development and commercialization of therapeutics for the treatment of neuropathic pain and hepatitis C. XTL is developing Bicifadine, a serotonin and norepinephrine reuptake inhibitor, for the treatment of neuropathic pain. XTL is also developing several novel pre-clinical hepatitis C small molecule inhibitors. XTL also has an active in-licensing and acquisition program designed to identify and acquire additional drug candidates. XTL is publicly traded on the NASDAQ, London, and Tel-Aviv Stock Exchanges (NASDAQ: XTLB; LSE: XTL; TASE: XTL).

Cautionary Statement

Some of the statements included in this press release, particularly those anticipating continued trading of the Company's ADRs on the NASDAQ Global Market, the potential transfer of trading to the NASDAQ Capital Market, the expected uninterrupted trading of the ADR, and the Company's ability to comply with NASDAQ Capital Market listing requirements, may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Risk factors that could adversely affect our operations are identified from time to time in our reports filed with the Securities and Exchange Commission and the London Stock Exchange, including our annual report on Form 20-F filed with the Securities and Exchange Commission on March 23, 2007. Any forward-looking statements set forth in this press release speak
'/>"/>

SOURCE XTL Biopharmaceuticals Ltd
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Medical College receives $377K to study brain disease
2. Lucigen receives $750K grant to boost biofuel yields
3. Medical College receives $1.4M cancer grant
4. Wisconsin biotech firm receives $107K NIH grant
5. InvivoSciences receives NIH grant for heart technology
6. Medical College receives $11 million grant to study high blood pressure
7. Madison business receives $115,000 of new state biofuels funding
8. Superior receives funds for technical training
9. UWM receives state funding for plastics research
10. GEs Centricity EHR receives federal certification
11. WHIE receives state eHealth Initiative contract
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... and SAN JOSE, California , ... biotechnology company developing antibody-drug conjugates for cancer, today announced the ... of Directors. Dr Reynolds has over 20 years, development experience ... Officer at Seattle Genetics. "I am delighted to ...
(Date:1/15/2014)... Toronto, Canada (PRWEB) January 15, 2014 ... perspectives on nonclinical and clinical safety assessment in biosimilars. ... a path for biosimilar drug development, however the complex ... regards to quality, safety and efficacy extremely challenging. Based ...
(Date:1/15/2014)... Houston, TX (PRWEB) January 15, 2014 ... Alzheimer’s disease, and about 1 in 3 seniors will ... ( source ). These jaw-dropping figures have shocked many ... function and, hopefully, help prevent these tragic age-related cognitive ...
(Date:1/15/2014)... The Microcompetition with Foreign DNA theory explains how latent viruses ... is the Epstein Barr Virus (EBV), and one of these ... chronic inflammatory disease that destroys the body’s joints. As predicted ... high concentrations of EBV DNA in their bodies (1). ...
Breaking Biology Technology:Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3
... unique, Rice University-based program that combines a traditional ... undergraduate research internship in nanotechnology, has been awarded ... Heiskell Award for Innovation in International Education. , ... and honor the most outstanding initiatives in international ...
... January 28 Nycomed has granted,Sepracor, Inc. ... marketing and,commercialisation rights for Ciclesonide in the ... a novel principle of action. It,is the ... for the,treatment of asthma and in the ...
... Joseph F. Finn, Jr.,CPA, the Assignee for the Benefit ... of the Company,s fixed assets for in,excess of $300,000 ... to,the high volume of requests for due diligence materials ... the Company has,created an online datasite that allows access ...
Cached Biology Technology:Rice wins innovation award for international program 2Nycomed's Ciclesonide to be Commercialised in the United States by Sepracor 2Nycomed's Ciclesonide to be Commercialised in the United States by Sepracor 3Nycomed's Ciclesonide to be Commercialised in the United States by Sepracor 4Nycomed's Ciclesonide to be Commercialised in the United States by Sepracor 5Nycomed's Ciclesonide to be Commercialised in the United States by Sepracor 6
(Date:4/17/2014)... to treat tuberculosis could be the basis for a ... fungal infections and parasites, yet evade resistance, according to ... , Led by U. of I. chemistry professor Eric ... SQ109 attacks the tuberculosis bacterium, how the drug can ... malaria and how targeting multiple pathways reduces the ...
(Date:4/17/2014)... NJ. April 16, 2014. Kessler Foundation has been ... million from the Department of Defense Spinal Cord ... principal investigator for the randomized, double-blinded, controlled, multi-site ... bone and muscle strength after spinal cord injury. ... & Engineering Research at Kessler Foundation. Two additional ...
(Date:4/17/2014)... per eight hundred births, Down syndrome - or trisomy ... intellectual disability. It results from a chromosomal abnormality where ... chromosome 21 (1% of the human genome). A study ... Department of Genetic Medicine and Development at the University ... Nature , shed light on how the extra chromosome ...
Breaking Biology News(10 mins):Multitarget TB drug could treat other diseases, evade resistance 2Kessler Foundation awarded Department of Defense grant for spinal cord injury research 2Trisomy 21: How an extra little chromosome throws the entire genome off balance 2Trisomy 21: How an extra little chromosome throws the entire genome off balance 3
... The common fruit fly circling your week-old peach has ... the insect,s eggshell formation. The paradoxical finding gives ... eggshell layer forms as it points to a likely ... biologist in the Medical College of Georgia Schools of ...
... plain with the odd hydrothermal vent, the seafloor appears ... paper being published May 29 in Nature. A ... mid-ocean ridge spreading system, representing potentially the largest surface ... geomicrobiologist Katrina Edwards, the studys corresponding author. While ...
... WEST LAFAYETTE, Ind. - Throughout the overlooked depths of ... important animal is rapidly disappearing. Until recently, the ... was a major food source for commercially important species ... salmon, trout and walleye rely. Scientists are employing ...
Cached Biology News:Fruit fly helps identify protein critical to eggshell formation that may be pesticide target 2Fruit fly helps identify protein critical to eggshell formation that may be pesticide target 3'Barren' seafloor teeming with microbial life 2'Barren' seafloor teeming with microbial life 3A Great Lakes mystery: The case of the disappearing species 2A Great Lakes mystery: The case of the disappearing species 3A Great Lakes mystery: The case of the disappearing species 4
... (CMV) pp65 Antigenemia Immunofluorescence Assay (IFA) is ... matrix protein pp65 of CMV in isolated ... Erythrocyte Lysis Buffer - ... mL of buffered ammonium chloride. (NH4CL) ...
ANTI NO-TRYPTOPHAN CONJUGATE...
ANTI DEOXY CORTICO...
... both 0.2 and 2.0 mL samples for freezing point determinations. Includes built-in ... reading capability with optional scanner. RS-232 port. Microprocessor-controlled autocalibration. Two-step Calibration. ... ... ...
Biology Products: